BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23036072)

  • 1. Associations of serum 25-hydroxyvitamin D with circulating PTH, phosphate and calcium in patients with primary hyperparathyroidism.
    Jayasena CN; Modi M; Palazzo F; De Silva A; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):838-43. PubMed ID: 23036072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seasonal changes in serum calcium, PTH and vitamin D levels in patients with primary hyperparathyroidism.
    Nevo-Shor A; Kogan S; Joshua BZ; Bahat-Dinur A; Novack V; Fraenkel M
    Bone; 2016 Aug; 89():59-63. PubMed ID: 27260647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism.
    Christensen SE; Nissen PH; Vestergaard P; Heickendorff L; Rejnmark L; Brixen K; Mosekilde L
    Eur J Endocrinol; 2008 Dec; 159(6):719-27. PubMed ID: 18787045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study.
    Moosgaard B; Vestergaard P; Heickendorff L; Melsen F; Christiansen P; Mosekilde L
    Eur J Endocrinol; 2006 Aug; 155(2):237-44. PubMed ID: 16868136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism.
    Untch BR; Barfield ME; Dar M; Dixit D; Leight GS; Olson JA
    Surgery; 2007 Dec; 142(6):1022-6. PubMed ID: 18063090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of vitamin D replacement in patients with normocalcaemic and hypercalcaemic primary hyperparathyroidism and coexisting vitamin D deficiency.
    Das G; Eligar V; Govindan J; Bondugulapati LN; Okosieme O; Davies S
    Ann Clin Biochem; 2015 Jul; 52(Pt 4):462-9. PubMed ID: 25468998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexisting primary hyperparathyroidism and sarcoidosis cause increased angiotensin-converting enzyme and decreased parathyroid hormone and phosphate levels.
    Lim V; Clarke BL
    J Clin Endocrinol Metab; 2013 May; 98(5):1939-45. PubMed ID: 23493435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal consequences of familial hypocalciuric hypercalcaemia vs. primary hyperparathyroidism.
    Christensen SE; Nissen PH; Vestergaard P; Heickendorff L; Rejnmark L; Brixen K; Mosekilde L
    Clin Endocrinol (Oxf); 2009 Dec; 71(6):798-807. PubMed ID: 19250271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism.
    Ozbey N; Erbil Y; Ademoğlu E; Ozarmağan S; Barbaros U; Bozbora A
    World J Surg; 2006 Mar; 30(3):321-6. PubMed ID: 16467981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature.
    Shah VN; Shah CS; Bhadada SK; Rao DS
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):797-803. PubMed ID: 24382124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief report: Does PTH increase with age, independent of 25-hydroxyvitamin D, phosphate, renal function, and ionized calcium?
    Carrivick SJ; Walsh JP; Brown SJ; Wardrop R; Hadlow NC
    J Clin Endocrinol Metab; 2015 May; 100(5):2131-4. PubMed ID: 25751107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure to normalize parathyroid hormone during treatment of vitamin D deficiency in Asian patients.
    Peacey SR; Wright D; Harries MJ
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):603-6. PubMed ID: 15521963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,25-dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis.
    Kinoshita Y; Taguchi M; Takeshita A; Miura D; Tomikawa S; Takeuchi Y
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6727-31. PubMed ID: 16159932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive escape from parathyroid suppression: a common phenomenon in primary hyperparathyroidism (a calcium clamp study).
    Sørensen HA; Schwarz P; Hyldstrup L; Transbøl I
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):309-15. PubMed ID: 8187293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism.
    Moosgaard B; Vestergaard P; Heickendorff L; Melsen F; Christiansen P; Mosekilde L
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):506-13. PubMed ID: 16268801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low vitamin D levels have become less common in primary hyperparathyroidism.
    Walker MD; Cong E; Lee JA; Kepley A; Zhang C; McMahon DJ; Bilezikian JP; Silverberg SJ
    Osteoporos Int; 2015 Dec; 26(12):2837-43. PubMed ID: 26084258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calculating an individual maxPTH to aid diagnosis of normocalemic primary hyperparathyroidism.
    Jin J; Mitchell J; Shin J; Berber E; Siperstein AE; Milas M
    Surgery; 2012 Dec; 152(6):1184-92. PubMed ID: 23102677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of calcium metabolism in type 1 myotonic dystrophy.
    Hlaing PM; Scott IA; Jackson RV
    Intern Med J; 2019 Nov; 49(11):1412-1417. PubMed ID: 30963668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism.
    Caron P; Maiza JC; Renaud C; Cormier C; Barres BH; Souberbielle JC
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):533-8. PubMed ID: 18782355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.